ReviewIranian journal of public health2025
Iran's Leap into the Future; an Exploration of Tissue Engineering Companies: Review Article.
Review in Iranian journal of public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This review represents the first comprehensive compilation of data on Iranian commercial, service, and research entities in the field of tissue engineering up to 2024. Methods: Through an extensive search of official websites, 56 companies were identified: 29 commercial enterprises, 17 service providers, and 10 research institutions. The majority (64%) of these companies are headquartered in Tehran, with many established post-2004. Results: Biomaterials account for half of the product portfolio, with 38% of ongoing research focused on this area. Although cell-based products currently make up only 12% of offerings, they are the subject of 38% of current research, indicating significant potential for future growth. Conclusion: This study provides a detailed overview of the development and future prospects of Iran's tissue engineering sector. The key conclusion emphasizes the need for an expanded focus on cell-based therapies and the establishment of stronger regulatory frameworks to facilitate the commercialization of innovative products. The review identifies key research gaps and proposes directions for future study, utilizing a descriptive methodology with in-depth data analysis and theoretical discussion.
Indexed as
Identifiers
40225257PMC11992919What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.